Mithra Completes Recruitment for Estelle® Phase III Study in US and Canada

  • Estelle® Phase III study in US/Canada remains on track to report top line data in Q1 2019
  • Study recruited 2148 women in total; 57% of subjects already completed over half the 13 treatment cycles
  • First subject completed the 13 cycle treatment as well as the end of study visit in October

Liège, Belgium, 30 October 2017 – Mithra (Euronext Brussels: MITRA), a company specialized in Women’s Health, today announces the completion of recruitment in the E4 Freedom Phase III study of Estelle® in the US and Canada. Estelle® is Mithra’s combined oral contraceptive (COC) candidate composed of 15 mg Estetrol (E4) and 3 mg drospirenone (DRSP). Top-line data, based on 13 cycles of treatment, remain on track to be reported in the first quarter of 2019.